CliffBio
small molecule

DIDANOSINE

DIDANOSINE

Loss of exclusivity—loss of exclusivity
CompanyPHARMOBEDIENT CONSULTING LLC

Drug detail

Brand nameDIDANOSINE
Active ingredientDIDANOSINE
Strength200MG
Dosage formCAPSULE, DELAYED REL PELLETS
RouteORAL
ModalitySmall molecule
FDA approvalApril 2010
Marketing statusDISCN

More from PHARMOBEDIENT CONSULTING LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DIDANOSINE patent cliff — loss of exclusivity — | CliffBio